<u>S</u>.B. NO. <u>1186</u>

#### JAN 2 7 2021

#### A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECT	ION 1. Section 329-14, Hawaii Revised Statutes, is
2	amended b	y amending subsection (b) to read as follows:
3	"(b)	Any of the following opiates, including their
4	isomers,	esters, ethers, salts, and salts of isomers, esters,
5	and ether	s, unless specifically excepted, whenever the existence
6	of these	isomers, esters, ethers, and salts is possible within
7	the speci	fic chemical designation:
8	(1)	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
9		<pre>phenethyl)-4-piperidinyl]-N-phenylacetamide);</pre>
10	(2)	Acetylmethadol;
11	(3)	Allylprodine;
12	(4)	Alphacetylmethadol (except levo-alphacetylmethadol,
13		levomethadyl acetate, or LAAM);
14	(5)	Alphameprodine;
15	(6)	Alphamethadol;
16	(7)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
17		phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
18		2-phenylethyl)-4-(N-propanilido) piperidine);

1	(8)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
2		thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
3	(9)	Benzethidine;
4	(10)	Betacetylmethadol;
5	(11)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
6		piperidinyl]-N-phenylpropanamide);
7	(12)	Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
8		phenethyl)-3-methyl-4-piperidinyl]-N-
9		phenylpropanamide);
10	(13)	Betameprodine;
11	(14)	Betamethadol;
12	(15)	Betaprodine;
13	(16)	Clonitazene;
14	(17)	Dextromoramide;
15	(18)	Diampromide;
16	(19)	Diethylthiambutene;
17	(20)	Difenoxin;
18	(21)	Dimenoxadol;
19	(22)	Dimepheptanol;
20	(23)	Dimethylthiambutene;
21	(24)	Dioxaphetyl butyrate;
22	(25)	Dipipanone;

```
Page 3
```

1	(26)	Ethylmethylthiambutene;
2	(27)	Etonitazene;
3	(28)	Etoxeridine;
4	(29)	Furethidine;
5	(30)	Hydroxypethidine;
6	(31)	Ketobemidone;
7	(32)	Levomoramide;
8	(33)	Levophenacylmorphan;
9	(34)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
10		<pre>piperidyl]-N-phenylpropanamide);</pre>
11	(35)	3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
12		4-piperidinyl]-N-phenylpropanamide);
13	(36)	Morpheridine;
14	(37)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
15		
	(38)	Noracymethadol;
16	(38) (39)	Noracymethadol; Norlevorphanol;
16 17	(39)	-
	(39)	Norlevorphanol;
17	(39) (40)	Norlevorphanol; Normethadone;
17 18	(39) (40) (41)	Norlevorphanol; Normethadone; Norpipanone;
17 18 19	(39) (40) (41)	Norlevorphanol; Normethadone; Norpipanone; Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-

,

1	(45)	Phenampromide;
2	(46)	Phenomorphan;
3	(47)	Phenoperidine;
4	(48)	Piritramide;
5	(49)	Proheptazine;
6	(50)	Properidine;
7	(51)	Propiram;
8	(52)	Racemoramide;
9	(53)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl) ethyl-4-
10		<pre>piperidinyl]-propanamide);</pre>
11	(54)	Tilidine;
12	(55)	Trimeperidine;
13	(56)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
14		(benzylfentanyl), its optical isomers, salts, and
15		salts of isomers;
16	(57)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-
17		phenylpropanamide (thenylfentanyl), its optical
18		isomers, salts, and salts of isomers;
19	(58)	N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
20		(acetyl fentanyl), its optical, positional, and
21		geometric isomers, salts, and salts of isomers;

1	(59)	AH-7921 (3,4-dichloro-N-[(1- dimethylamino)
2		cyclohexylmethyl]benzamide), its isomers, esters,
3		ethers, salts, and salts of isomers, esters, and
4		ethers;
5	(60)	N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
6		isomers, esters, ethers, salts, and salts of isomers,
7		esters, and ethers (Other names: Butyryl fentanyl);
8	(61)	N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-
9		yl]-N-phenylpropionamide, its isomers, esters, ethers,
10		salts and salts of isomers, esters, and ethers (Other
11		<pre>names: beta-hydroxythiofentanyl);</pre>
12	(62)	N-(1-phenthylpiperidin-4-y1)-N-phenylfuran-2-
13		carboxamide, its isomers, esters, ethers, salts, and
14		salts of isomer, esters, and ethers (other names:
15		Furanyl fentanyl);
16	(63)	3,4-dicholoro-N-[2-(dimethylamino)cyclohexyl]-N-
17		methylbenzamide, its isomers, esters, ethers, salts
18		and salts of isomers, esters, and ethers (Other names:
19		U-47700);
20	(64)	4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl
21		fentanyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-
22		4-yl)isobutyramide];

```
Page 6
```

1	(65)	Acryl fentanyl or acryloylfentanyl [N-(1-
2		phenethylpiperidin-4-yl)-N-phenylacrylamide]; [ <del>and</del> ]
3	(66)	Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-
4		phenethylpiperidin-4-yl)acetamide][ <del>.</del> ] <u>;</u>
5	(67)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
6		phenylcyclopropanecarboxamide;
7	(68)	Methoxyacetyl fentanyl (2-methoxy-N-(1-
8		phenethylpiperidin-4-yl)-N-phenylacetamide);
9	(69)	ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-
10		phenethylpiperidin-4-yl)propionamide); other name: 2-
11		fluorofentanyl); and
12	(70)	para-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
13		phenethylpiperidin-4-yl)butyramide)."
14	SECT	ION 2. Section 329-14, Hawaii Revised Statutes, is
15	amended b	y amending subsection (e) to read as follows:
16	"(e)	Depressants. Unless specifically excepted, the
17	schedule	shall include any material, compound, mixture, or
18	preparati	on which contains any quantity of the substance:
19	(1)	Mecloqualone; [ <del>or</del> ]
20	(2)	Methaqualone[-];

1	<u>(3) Eti</u>	zolam (including its optical, positional, and
2	geor	metric isomers, salts, and salts of isomers, where
3	pos	sible); or
4	(4) Flua	alprazolam (including its optical, positional, and
5	geor	netric isomers, salts, and salts of isomers, where
6	pos	sible)."
7	SECTION 3	3. Section 329-14, Hawaii Revised Statutes, is
8	amended by ame	ending subsection (g) to read as follows:
9	"(g) Ang	y of the following cannabinoids, their salts,
10	isomers, and s	salts of isomers, unless specifically excepted,
11	whenever the e	existence of these salts, isomers, and salts of
12	isomers is pos	ssible within the specific chemical designation:
13	(1) Tet:	cahydrocannabinols; meaning tetrahydrocannabinols
14	natu	rally contained in a plant of the genus Cannabis
15	(car	nnabis plant), as well as synthetic equivalents of
16	the	substances contained in the plant, or in the
17	res	nous extractives of Cannabis, sp. or synthetic
18	subs	stances, derivatives, and their isomers with
19	sim	llar chemical structure and pharmacological
20	act:	ivity to those substances contained in the plant,
21	such	n as the following: Delta 1 cis or trans
22	tet	rahydrocannabinol, and their optical isomers; Delta

1		6 cis or trans tetrahydrocannabinol, and their optical
2		isomers; and Delta 3,4 cis or trans-
3		tetrahydrocannabinol, and its optical isomers (since
4		nomenclature of these substances is not
5		internationally standardized, compounds of these
6		structures, regardless of numerical designation of
7		atomic positions, are covered);
8	(2)	Naphthoylindoles; meaning any compound containing a 3-
9		(1-naphthoyl)indole structure with substitution at the
10		nitrogen atom of the indole ring by a alkyl,
11		haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl,
12		1-(N-methyl-2-piperidinyl)methyl or 2-(4-
13		morpholinyl)ethyl group, whether or not further
14		substituted in the indole ring to any extent and
15		whether or not substituted in the naphthyl ring to any
16		extent;
17	(3)	Naphthylmethylindoles; meaning any compound containing
18		a 1H-indol-3-yl-(1-naphthyl) methane structure with
19		substitution at the nitrogen atom of the indole ring
20		by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
22		2-(4-morpholinyl) ethyl group whether or not further

#### <u>S</u>.B. NO. 1186

substituted in the indole ring to any extent and
whether or not substituted in the naphthyl ring to any
extent;

4 (4) Naphthoylpyrroles; meaning any compound containing a 5 3-(1-naphthoyl)pyrrole structure with substitution at 6 the nitrogen atom of the pyrrole ring by a alkyl, 7 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 8 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) 9 ethyl group whether or not further substituted in the 10 pyrrole ring to any extent, whether or not substituted 11 in the naphthyl ring to any extent;

12 (5) Naphthylmethylindenes; meaning any compound containing
13 a naphthylideneindene structure with substitution at
14 the 3-position of the indene ring by a alkyl,

15 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 16 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) 17 ethyl group whether or not further substituted in the 18 indene ring to any extent, whether or not substituted 19 in the naphthyl ring to any extent;

20 (6) Phenylacetylindoles; meaning any compound containing a
21 3-phenylacetylindole structure with substitution at
22 the nitrogen atom of the indole ring by a alkyl,

## <u>S</u>.B. NO. 1186

1		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
2		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
3		ethyl group whether or not further substituted in the
4		indole ring to any extent, whether or not substituted
5		in the phenyl ring to any extent;
6	(7)	Cyclohexylphenols; meaning any compound containing a
7		2-(3-hydroxycyclohexyl) phenol structure with
8		substitution at the 5-position of the phenolic ring by
9		a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
10		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
11		2-(4-morpholinyl) ethyl group whether or not
12		substituted in the cyclohexyl ring to any extent;
13	(8)	Benzoylindoles; meaning any compound containing a 3-
14		(benzoyl) indole structure with substitution at the
15		nitrogen atom of the indole ring by a alkyl,
16		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
17		1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
18		morpholinyl) ethyl group whether or not further
19		substituted in the indole ring to any extent and
20		whether or not substituted in the phenyl ring to any
21		extent;

1	(9)	<pre>[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)</pre>
2		pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
3		naphthalenylmethanone (another trade name is WIN
4		55,212-2);
5	(10)	(6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
6		methyloctan-2-yl)-6a,7,10,10a-
7		tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
8		HU-210/HU-211);
9	(11)	Tetramethylcyclopropanoylindoles; meaning any compound
10		containing a 3-tetramethylcyclopropanoylindole
11		structure with substitution at the nitrogen atom of
12		the indole ring by an alkyl, haloalkyl, cyanoalkyl,
13		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
14		<pre>methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,</pre>
15		1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
16		morpholinyl)methyl, or tetrahydropyranylmethyl group,
17		whether or not further substituted in the indole ring
18		to any extent and whether or not substituted in the
19		tetramethylcyclopropyl ring to any extent;
20	(12)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
21		its optical, positional, and geometric isomers, salts,
22		and salts of isomers (Other names: APINACA, AKB48);

```
Page 12
```

1	(13)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
2		optical, positional, and geometric isomers, salts, and
3		salts of isomers (Other names: PB-22; QUPIC);
4	(14)	Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
5		carboxylate, its optical, positional, and geometric
6		isomers, salts, and salts of isomers (Other names: 5-
7		fluoro-PB-22; 5F-PB-22);
8	(15)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
9		fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
10		positional, and geometric isomers, salts, and salts of
11		isomers (Other names: AB-FUBINACA);
12	(16)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
13		indazole-3-carboxamide, its optical, positional, and
14		geometric isomers, salts, and salts of isomers (Other
15		names: ADB-PINACA);
16	(17)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
17		(cyclohexylmethyl)-1H-indazole-3-carboxamide, its
18		optical, positional, and geometric isomers, salts, and
19		salts of isomers (Other names: AB-CHMINACA);
20	(18)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
21		indazole-3-carboxamide, and geometric isomers, salts,
22		and salts of isomers (Other names: AB-PINACA);

1	(19)	[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
2		yl)methanone, and geometric isomers, salts, and salts
3		of isomers (Other names: THJ-2201);
4	(20)	Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-
5		valinate, and geometric isomers, salts, and salts of
6		isomers (Other names: $FUB-AMB[+][+]$ , Methyl 2-(1-(4-
7		fluorobenzyl)-1H-indazole-3-carboxamido)-3-
8		<pre>methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);</pre>
9	(21)	(S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
10		carboxamido)-3-methylbutanoate, and geometric isomers,
11		salts, and salts of isomers (Other names: 5-fluoro-
12		AMB, 5-fluoro-AMP);
13	(22)	N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
14		indazole-3-carboxamide, and geometric isomers, salts,
15		and salts of isomers (Other names: AKB48 N-(5-
16		fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
17		analog, 5F-APINACA);
18	(23)	N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
19		geometric isomers, salts, and salts of isomers (Other
20		<pre>names: STS-135, 5F-APICA; 5-fluoro-APICA);</pre>

```
Page 14
```

•

## <u>S</u>.B. NO. <u>1186</u>

1	(24)	Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
2		carboxylate, and geometric isomers, salts, and salts
3		of isomers (Other names: NM2201);
4	(25)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
5		(cyclohexylmethyl)-1H-indazole-3-carboxamide, and
6		geometric isomers, salts, and salts of isomers (Other
7		names: MAB-CHMINACA and ADB-CHMINACA);
8	(26)	Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
9		carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
10		ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
11		positional, and geometric isomers, salts, and salts of
12		isomers; and
13	(27)	1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
14		carboxamide (CUMYL-4CN-BINACA), its optical,
15		positional, and geometric isomers, salts, and salts of
16		isomers; also known as SGT-78, 4-CN-CUMYL-BINACA;
17		CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL-
18		BUTINACA."
19	SECT	ION 4. Section 329-16, Hawaii Revised Statutes, is
20	amended b	y amending subsection (f) to read as follows:

.

## **S**.B. NO. **1186**

1	"(f) Immediate precursor. Unless listed in another
2	schedule, any material, compound, mixture, or preparation which
3	contains any quantity of the following substances:
4	(1) Immediate precursor to amphetamine and
5	methamphetamine:
6	(A) Phenylacetone, phenyl-2-propanone(P2P), benzyl
7	methyl ketone, methyl benzyl ketone;
8	(2) Immediate precursors to phencyclidine (PCP):
9	(A) 1-phenylcyclohexylamine; [and] <u>or</u>
10	(B) 1-piperidinocyclohexanecarbonitrile(PCC); or
11	(3) Immediate precursor to Fentanyl:
12	(A) 4-anilino-N-phenethyl-4-piperidine (ANPP)[+]; or
13	(B) N-phenyl-N-(piperidin-4-yl)propionamide
14	<pre>(norfentanyl)."</pre>
15	SECTION 5. Section 329-20, Hawaii Revised Statutes, is
16	amended by amending subsection (b) to read as follows:
17	"(b) Depressants. Any material, compound, mixture, or
18	preparation which contains any quantity of the following
19	substances, including its salts, isomers, esters, ethers, and
20	salts of isomers, whenever the existence of these isomers,
21	esters, ethers, and salts is possible within the specific
22	chemical designation, that has a degree of danger or probable

1 danger associated with a depressant effect on the central

2 nervous system:

- 3 (1) Alprazolam;
- 4 (2) Barbital;
- 5 (3) Bromazepam;
- **6** (4) Butorphanol;
- 7 (5) Camazepam;
- 8 (6) Carisoprodol;
- 9 (7) Chloral betaine;
- 10 (8) Chloral hydrate;
- 11 (9) Chlordiazepoxide;
- **12** (10) Clobazam;
- 13 (11) Clonazepam;
- 14 (12) Clorazepate;
- 15 (13) Clotiazepam;
- 16 (14) Cloxazolam;
- 17 (15) Delorazepam;
- 18 (16) Dichloralphenazone (Midrin);
- **19** (17) Diazepam;
- **20** (18) Estazolam;
- 21 (19) Ethchlorvynol;
- 22 (20) Ethinamate;

1 (21)	Ethyl	loflazepate;
--------	-------	--------------

- 2 (22) Fludiazepam;
- 3 (23) Flunitrazepam;
- 4 (24) Flurazepam;
- 5 (25) Fospropofol (Lusedra);
- **6** (26) Halazepam;
- 7 (27) Haloxazolam;
- 8 (28) Ketazolam;
- 9 (29) Loprazolam;
- 10 (30) Lorazepam;
- 11 (31) Lormetazepam;
- 12 (32) Mebutamate;
- 13 (33) Medazepam;
- 14 (34) Meprobamate;
- 15 (35) Methohexital;
- 16 (36) Methylphenobarbital (mephorbarbital);
- 17 (37) Midazolam;
- 18 (38) Nimetazepam;
- 19 (39) Nitrazepam;
- 20 (40) Nordiazepam;
- **21** (41) Oxazepam;
- **22** (42) Oxazolam;

#### <u>S</u>.B. NO. 1186

- 1 (43) Paraldehyde;
- 2 (44) Petrichloral;
- 3 (45) Phenobarbital;
- 4 (46) Pinazepam;
- 5 (47) Prazepam;
- 6 (48) Quazepam;
- 7 (49) Suvorexant;
- 8 (50) Temazepam;
- 9 (51) Tetrazepam;
- 10 (52) Triazolam;
- **11** (53) Zaleplon;
- **12** (54) Zolpidem; [and]
- 13 (55) Zopiclone (Lunesta) [-]; and
- 14 (56) Brexanolone."

15 SECTION 6: Section 329-20, Hawaii Revised Statutes, is 16 amended by amending subsection (d) to read as follows:

17 "(d) Stimulants. Unless listed in another schedule, any 18 material, compound, mixture, or preparation which contains any 19 quantity of the following substances having a stimulant effect 20 on the central nervous system, including its salts, isomers, and 21 salts of such isomers whenever the existence of such salts,

## <u>S</u>.B. NO. **II8L**

1	isomers,	and salts of isomers is possible within the specific
2	chemical	designation:
3	(1)	Cathine ((+)-norpseudoephedrine);
4	(2)	Diethylpropion;
5	(3)	Fencamfamin;
6	(4)	Fenproporex;
7	(5)	Mazindol;
8	(6)	Mefenorex;
9	(7)	Modafinil;
10	(8)	Phentermine;
11	(9)	Pemoline (including organometallic complexes and
12		chelates thereof);
13	(10)	Pipradrol;
14	(11)	Sibutramine;
15	(12)	SPA (1-dimethylamino-1,2-diphenylethane, lefetamine);
16		[and]
17	(13)	Lorcaserin[-]; and
18	(14)	Solriamfetol."
19	SEC	TION 7. Section 329-22, Hawaii Revised Statutes, is
20	amended	to read as follows:
21	"§3:	29-22 Schedule V. (a) The controlled substances
22	listed in	n this section are included in schedule V.

• • •

.

1	(b)	Narcotic drugs containing nonnarcotic active medicinal
2	ingredien	ts. Any compound, mixture, or preparation containing
3	limited q	uantities of any of the following narcotic drugs, which
4	also cont	ains one or more nonnarcotic active medicinal
5	ingredien	ts in sufficient proportion to confer upon the
6	compound,	mixture, or preparation, valuable medicinal qualities
7	other that	n those possessed by the narcotic drug alone:
8	(1)	Not more than 200 milligrams of codeine, or any of its
9		salts, per 100 milliliters or per 100 grams;
10	(2)	Not more than 100 milligrams of dihydrocodeine, or any
11		of its salts, per 100 milliliters or per 100 grams;
12	(3)	Not more than 100 milligrams of ethylmorphine, or any
13		of its salts, per 100 milliliters or per 100 grams;
14	(4)	Not more than 2.5 milligrams of diphenoxylate and not
15		less than 25 micrograms of atropine sulfate per dosage
16		unit;
17	(5)	Not more than 100 milligrams of opium per 100
18		milliliters or per 100 grams; and
19	(6)	Not more than 0.5 milligram of difenoxin and not less
20		than 25 micrograms of atropine sulfate per dosage
21		unit.

### <u>S</u>.B. NO. 1186

1	(C)	Stimulants. Unless specifically exempted or excluded
2	or unless	listed in another schedule, any material, compound,
3	mixture, o	or preparation that contains any quantity of the
4	following	substances having a stimulant effect on the central
5	nervous sy	ystem, including its salts, isomers, and salts of
6	isomers.	
7	(d)	Depressants. Unless specifically exempted or excluded
8	or unless	listed in another schedule, any material, compound,
9	mixture, o	or preparation that contains any quantity of the
10	following	substances having a depressant effect on the central
11	nervous s	ystem, including its salts, isomers, and salts of
12	isomers:	
13	(1)	Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
14		<pre>propionamide], (Vimpat);</pre>
15	(2)	Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
16		acid]; and
17	(3)	Brivaracetam ((2S)-2[(4R)-2-oxo-4-propylpyrrolidin-1-
18		yl]butanamide) (Other names: BRV; UCB-34714; Briviact)
19		and its salts.
20	[ <del>(</del> e <del>)</del>	Approved cannabidiol drugs. A drug product in
21	finished (	dosage formulation that has been approved by the United
22	<del>States Fo</del>	od and Drug Administration that contains cannabidiol

## <u>S</u>.B. NO. 1186

1	<del>(2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-</del>
2	pentyl-1,3-benzenediol) derived from cannabis and no more than
3	0.1 percent (w/w) residual tetrahydrocannabinols.]"
4	SECTION 8. Statutory material to be repealed is bracketed
5	and stricken. New statutory material is underscored.
6	SECTION 9. This Act shall take effect upon its approval.
7	Anno MA
8	INTRODUCED BY:
9	BY REQUEST
10	

### <u>S</u>.B. NO. 1186

#### Report Title:

Uniform Controlled Substances Act

#### Description:

Updates the Uniform Controlled Substances Act, chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal controlled substances law as required by section 329-11, Hawaii Revised Statutes.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

#### SB. NO. 1186

#### JUSTIFICATION SHEET

- DEPARTMENT: Public Safety
- TITLE: A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.
- PURPOSE: To update chapter 329, Hawaii Revised Statutes (HRS), to make it consistent with amendments in the federal controlled substances law and an emergency state scheduling action.
- MEANS: Amend sections 329-14(b), (e), and (g), 329-16(f), 329-20(b) and (d), and 329-22, HRS.
- JUSTIFICATION: Section 329-11, HRS, requires that the Department of Public Safety recommend corresponding changes in Hawaii law.

<u>Impact on the public:</u> This bill is intended to protect the public by updating Hawaii's controlled substance schedules consistent with Federal law.

Impact on the department and other agencies: These proposed amendments would assist the Department's Narcotics Enforcement Division in clarifying regulations of the Uniform Controlled Substances Act.

- GENERAL FUND: None.
- OTHER FUNDS: None.
- PPBS PROGRAM DESIGNATION: PSD 502.

OTHER AFFECTED AGENCIES:

Department of Health Food and Drug Branch; federal, state, and county law enforcement.

EFFECTIVE DATE: Upon approval.